A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated Advanced EGFRm NSCLC
Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated EGFRm NSCLC
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAR5941
U.S. Govt. ID: NCT03381274
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to look at whether the combination of MEDI9447 and osimertinib or MEDI9447 and AZD4635 will improve the outcome in subjects with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC).
This study is closed
Investigator
Catherine Shu, MD
Do You Qualify?
Do you weigh more than 35 kg (77 pounds)? Yes No
Have you been diagnosed with advanced/metastatic NSCLC? Yes No
Have you received prior therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE